Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Income (2016 - 2025)

Historic Net Income for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to -$108.0 million.

  • Agios Pharmaceuticals' Net Income fell 1193.08% to -$108.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$414.6 million, marking a year-over-year decrease of 16182.69%. This contributed to the annual value of -$412.8 million for FY2025, which is 16126.85% down from last year.
  • Agios Pharmaceuticals' Net Income amounted to -$108.0 million in Q4 2025, which was down 1193.08% from -$103.4 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Net Income registered a high of $2.0 billion during Q1 2021, and its lowest value of -$112.5 million during Q2 2025.
  • Its 4-year average for Net Income is $116.4 million, with a median of -$88.0 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first soared by 438287.33% in 2021, then crashed by 11091.16% in 2025.
  • Over the past 4 years, Agios Pharmaceuticals' Net Income (Quarter) stood at $4.0 million in 2021, then crashed by 2524.56% to -$95.9 million in 2023, then dropped by 0.61% to -$96.5 million in 2024, then decreased by 11.93% to -$108.0 million in 2025.
  • Its Net Income stands at -$108.0 million for Q4 2025, versus -$103.4 million for Q3 2025 and -$112.5 million for Q2 2025.